Evidence map›Paper›PMID 30479769›Full record

ArticleBiomarker research2018

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Marte Karen Brattås, Kyrre Lilleeng, Randi Hovland, Ingvild Jenssen Lægreid, Marta Vorland, Friedemann Leh, Øystein Bruserud, Bjørn Tore Gjertsen, Håkon Reikvam

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomarker research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Proteomics techniques in protein biomarker discovery.Quantitative biology (Beijing, China) · 2024
    Review
  2. Review
  3. Acute Myeloid Leukemia withCase reports in oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Marte Karen Brattås1Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
Kyrre Lilleeng1Department of Medicine, Haraldsplass Deaconess Hospital, Bergen, Norway.
Randi Hovland2Department of Medical Genetics, Haukeland University Hospital, Bergen, Norway.
Ingvild Jenssen Lægreid3Department of Laboratory Medicine, University Hospital of Northern Norway, Tromsø, Norway.
Marta Vorland4Department of Medical Biochemistry, Haukeland University Hospital, Bergen, Norway.
Friedemann Leh5Department of Pathology, Haukeland University Hospital, Bergen, Norway.
Øystein Bruserud6Department of Clinical Science, University of Bergen, Bergen, Norway.
Bjørn Tore Gjertsen6Department of Clinical Science, University of Bergen, Bergen, Norway.
Håkon Reikvam6Department of Clinical Science, University of Bergen, Bergen, Norway.
Haukeland University Hospital · NOHaraldsplass Diakonale Sykehus · NOUniversity of Bergen · NOUniversity Hospital of North Norway · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA feature of myeloproliferative neoplasia is transforming to more aggressive and malignant myeloid neoplasia, including acute myeloid leukemia. Different pathogenesis mechanisms participate in transformation, including transformation of existing potential preleukemic clones, since CASE PRESENTATION: Here, we present an 80 year old man with a

conclusionThe case illustrates the potential of leukemic transformation to Philadelphia chromosome positive myeloid malignancies from potential existing preleukemic clones, and the awareness of such an evolution among patients with myeloproliferative neoplasms. Tyrosine kinases have potential effect also in patients presenting without chronic myeloid leukemia and with rare

Indexed as

AMLClonal evolutionJAK2Philadelphia chromosomePrimary myelofibrosis

Identifiers

PMID30479769
PMCPMC6249888
OpenAlexW2900634538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.